Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Doxorubicin 12Cyclophosphamide 11Temozolomide 9Biopsy 9Radiation 8atezolizumab 7Radiotherapy 7X-Rays 6Vincristine 6Nivolumab 6Etoposide 6Bevacizumab 6pembrolizumab 5liposomal doxorubicin 5fludarabine 5cabozantinib 5Sirolimus 5Phantoms, Imaging 5Irinotecan 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Nuclear Medicine Department, Hospital 4temsirolimus 3palbociclib 3olaparib 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lomustine × Sarcoma × 30 days × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡